Cirmtuzumab
Humanized | |
|---|---|
| Target | ROR1 |
| Clinical data | |
| Other names | UC-961 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody.[1][2]
It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).[3][4]
References
- .
- ^ "Researchers to test novel drug combination against toughest breast cancers". Medical Express. 2018-08-27.
- ^ Clinical trial number NCT03420183 for "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies" at ClinicalTrials.gov
- ^ "1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo". Lymphoma News Today. 2018-05-18.